Marizyme, Inc. (MRZM)

OTCMKTS: MRZM · Delayed Price · USD
1.12
0.00 (0.00%)
Dec 2, 2022 4:00 PM EST - Market closed
Market Cap 11.30M
Revenue (ttm) 76,148
Net Income (ttm) -20.12M
Shares Out 10.13M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 101
Open 1.03
Previous Close 1.12
Day's Range 1.01 - 1.12
52-Week Range 1.01 - 3.25
Beta 0.26
Analysts n/a
Price Target n/a
Earnings Date n/a

About MRZM

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In add... [Read more]

Industry Software
Founded 2007
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol MRZM
Full Company Profile

News

Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Tradema...

Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark Office (U...

10 months ago - GlobeNewsWire

Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health Logic In...

11 months ago - GlobeNewsWire

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

JUPITER, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnos...

11 months ago - GlobeNewsWire

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to pre...

11 months ago - GlobeNewsWire

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executi...

1 year ago - GlobeNewsWire

Marizyme, Inc. Issues Letter to Shareholders

JUPITER, Fla., March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tiss...

1 year ago - PRNewsWire

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue...

1 year ago - PRNewsWire

Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations an...

JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue ...

1 year ago - PRNewsWire

Marizyme Announces Approval for DuraGraft® in India

JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue...

1 year ago - PRNewsWire

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surger...

JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, orga...

1 year ago - PRNewsWire

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digi...

JUPITER, Fla., Jan. 7, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue ...

1 year ago - PRNewsWire